Tag: Anti tb drugs

Globally, millions of people fall ill with tuberculosis (TB) each year, making it a persistent public health threat. For active disease caused by drug-susceptible *Mycobacterium tuberculosis*, there is no single "drug of choice" but rather a carefully structured, multi-phase regimen using a combination of first-line medications. This approach is crucial to ensure efficacy, minimize treatment duration, and prevent the emergence of drug resistance.

According to the World Health Organization (WHO), directly observed treatment, short-course (DOTS) is a highly effective strategy for managing tuberculosis, with its success fundamentally dependent on a specific combination of first-line anti-TB drugs. This treatment approach, which ensures patients complete their full medication course under supervision, is crucial for preventing treatment failure and the spread of drug-resistant strains.

Peripheral neuropathy (PN) is a serious condition that commonly affects patients with tuberculosis (TB) [1.2.3]. While other drugs are more frequent culprits, the question remains: **Can pyrazinamide cause peripheral neuropathy?** This article examines the evidence.